Loomis, Sayles & Company
BIO icon

Loomis, Sayles & Company’s Bio-Rad Laboratories Class A BIO Stock Holding History

Loomis, Sayles & Company’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-143
Closed -$60K – 871
2022
Q3 		$60K Sell
143
-285
-67% -$142K ﹤0.01% 561
2022
Q2 		$212K Sell
428
-363
-46% -$189K ﹤0.01% 492
2022
Q1 		$446K Buy
791
+363
+85% +$219K ﹤0.01% 499
2021
Q4 		$323K Buy
+428
New +$320K ﹤0.01% 535
2021
Q1 		– Sell
-20
Closed -$12K – 842
2020
Q4 		$12K Buy
+20
New +$11.4K ﹤0.01% 689
2015
Q4 		– Sell
-77
Closed -$10K – 1050
2015
Q3 		$10K Buy
+77
New +$11.1K ﹤0.01% 902

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return